



Date: 2 October 2019

Sydney, Australia

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

Noxopharm 2019 Annual General Meeting Details

- Wednesday November 20, 2019 at 2pm
 - Museum of Sydney, corner of Phillip and Bridge Streets, Sydney. NSW
-

Sydney, 2 October 2019:

Noxopharm (ASX: NOX) is pleased to announce details of its 2019 Annual General Meeting to the market.

In addition to voting formalities, the Chair of the Board will present an overview of the year's activities, achievements and plans for the year ahead. A clinical program and research update also will be provided.

The event will be webcast and registration details to be provided soon.

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.

www.noxopharm.com

Investor & Corporate Enquiries

Media Contact Australia

Prue Kelly
M: 0459 022 445
E: Prue.Kelly@noxopharm.com

Company Secretary:

David Franks
T: +61 2 9299 9690
E: David.Franks@atomicgroup.com.au



Media Contact USA:

Frank de Maria

Purposeful Communications

T: +1 347 647 0284

E: frank.demaria@purposefulcommunications.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.